Fecal microbiota transplantation induces hepatitis B virus e‐antigen (HBeAg) clearance in patients with positive HBeAg after long‐term antiviral therapy

Ren, Yandan; Ye, Zhen‐Shi; Yang, Liu-Zhu; Jin, Lixin; Wei, Wenjun; Deng, Yongyue; Chen, Xiaoxiao; Chen, Xiao; Yu, Xiang; Xu, Hui; Xu, Li-Zhu; Tang, Yun-Na; Zhou, Fei; Wang, Xuelian; Chen, Meiya; Chen, Ligang; Hong, Mei‐Zhu; Ren, Jianlin; Pan, Jin‐Shui

doi:10.1002/hep.29008

Cited by 124 publications

(112 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Notably, FMT was performed in 18 patients with persistent positive HBeAg. 104 FMT was effective for these patients via inducing HBeAg clearance, suggesting that regulating intestinal microbiota might be beneficial to chronic hepatitis B treatment. A Phase I clinical trial demonstrated that FMT restored antibiotic-induced microbial dysbiosis in patients with advanced liver cirrhosis.…”

Section: Fmt For Digestive System Cancersmentioning

confidence: 95%

“…FMT led to rapid amelioration of appetite and hyperbilirubinemia. Notably, FMT was performed in 18 patients with persistent positive HBeAg . FMT was effective for these patients via inducing HBeAg clearance, suggesting that regulating intestinal microbiota might be beneficial to chronic hepatitis B treatment.…”

Section: Fmt As a Possible Therapy For Various Type Of Cancers And Camentioning

confidence: 99%

See 1 more Smart Citation

Fecal microbiota transplantation in cancer management: Current status and perspectives

Chen

Jin

et al. 2018

Intl Journal of Cancer

223

161

View full text Add to dashboard Cite

The human gut is home to a large and diverse microbial community, comprising about 1,000 bacterial species. The gut microbiota exists in a symbiotic relationship with its host, playing a decisive role in the host's nutrition, immunity and metabolism. Accumulating studies have revealed the associations between gut dysbiosis or some special bacteria and various cancers. Emerging data suggest that gut microbiota can modulate the effectiveness of cancer therapies, especially immunotherapy. Manipulating the microbial populations with therapeutic intent has become a hot topic of cancer research, and the most dramatic manipulation of gut microbiota refers to fecal microbiota transplantation (FMT) from healthy individuals to patients. FMT has demonstrated remarkable clinical efficacy against Clostridium difficile infection (CDI) and it is highly recommended for the treatment of recurrent or refractory CDI. Lately, interest is growing in the therapeutic potential of FMT for other diseases, including cancers. We briefly reviewed the current researches about gut microbiota and its link to cancer, and then summarized the recent preclinical and clinical evidence to indicate the potential of FMT in cancer management as well as cancer‐treatment associated complications. We also presented the rationale of FMT for cancer management such as reconstruction of intestinal microbiota, amelioration of bile acid metabolism, and modulation of immunotherapy efficacy. This article would help to better understand this new therapeutic approach for cancer patients by targeting gut microbiota.

show abstract

Section: Fmt For Digestive System Cancersmentioning

confidence: 95%

Section: Fmt As a Possible Therapy For Various Type Of Cancers And Camentioning

confidence: 99%

Fecal microbiota transplantation in cancer management: Current status and perspectives

Chen

Jin

et al. 2018

Intl Journal of Cancer

223

161

View full text Add to dashboard Cite

show abstract

“…Interestingly, although FMT from healthy donors often bring about a good result to receipts, when comparing receipts gut microbiota before and after FMT and check the similarity to the donors' gut microbiota, it found that the receipts gut microbiota was obviously changed by FMT, however, the similarity of the receipts' gut microbiota after FMT to the donor's was not as high as expected, especially when the receipts were not germ-free subjects like human or SPF animals. 38 This may attribute to colonization ability of the microbes, some may easy to win out in the competition with intrinsical microbes or set down in the receipts' gut, some may not easy to win an ecological niche.…”

Section: Discussionmentioning

confidence: 99%

Novel role of hesperidin improve obesity in HFD mice by modulating the composition of the gut microbiota

Liu

Song

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Hesperidin is a plant-derived dihydroflavone derivatives with multiple pharmacological function. Obesity is associated with low-grade chronic inflammation and intestinal dysbiosis. We examined the possibility that hesperidin may prevent diet-induced obesity by modulating the composition of the gut microbiota. High-fat diet (HFD)-fed mice were treated with hesperidin. Its effects on the gut microbiota were assessed by horizontal faecal microbiota transplantation (FMT) and 16S rDNA-based microbiota analysis.ResultsGut microbiota analysis revealed that hesperidin selectively promoted the growth of beneficial Lactobacillus salivarius and harmful Staphylococcus sciuri, Desulfovibrio C21_c20 and inhibiting beneficial Bifidobacterium pseudolongum, Mucispirillum schaedleri and harmful Helicobacter ganmani , Helicobacter hepaticus . in HFD-fed mice. However, hesperidin reverses obesity, inflammation and improves gut integrity in HFD-fed mice. The anti-obesity effects and hesperidin-modulated Lactobacillus salivarius, Desulfovibrio C21_c20, Mucispirillum schaedleri and Helicobacter hepaticus were transmissible via horizontal faces transfer from hesperidin-treated mice to HFD-fed mice.Conclusions Hesperidin has a role to reduce body weight and reverse HFD-related disorders in HFD-fed mice by enriching some beneficial and inhibiting harmful microbes.

show abstract

“…It has been indicated that chronic HBV patients with liver cirrhosis have different microbiota compared to healthy people (112, 113). A recent case-controlled, open-label pilot trial has demonstrated the efficacy of fecal microbiota transplantation in HBV e-antigen positive patients, especially in those who could not otherwise cease the oral antiviral treatment even after long-term treatment (115). This suggests a benefit from modifying the gut microbiota for chronic HBV treatment, however, larger trials will be needed to draw a definite conclusion in the future.…”

Section: Gut Microbiota and Liver Diseasesmentioning

confidence: 99%

Remote Sensing Between Liver and Intestine: Importance of Microbial Metabolites

Cui

2017

Curr Pharmacol Rep

View full text Add to dashboard Cite

Recent technological advancements including metagenomics sequencing and metabolomics have allowed the discovery of critical functions of gut microbiota in obesity, malnutrition, neurological disorders, asthma, and xenobiotic metabolism. Classification of the human gut microbiome into distinct “enterotypes” has been proposed to serve as a new paradigm for understanding the interplay between microbial variation and human disease phenotypes, as many organs are affected by gut microbiota modifications during the pathogenesis of diseases. Gut microbiota remotely interacts with liver and other metabolic organs of the host through various microbial metabolites that are absorbed into the systemic circulation. Purpose of review The present review summarizes recent literature regarding the importance of gut microbiota in modulating the physiological and pathological responses of various host organs, and describes the functions of the known microbial metabolites that are involved in this remote sensing process, with a primary focus on the gut microbiota-liver axis. Recent findings Under physiological conditions, gut microbiota modulates the hepatic transcriptome, proteome, and metabolome, most notably down-regulating cytochrome P450 3a mediated xenobiotic metabolism. Gut microbiome also modulates the rhythmicity in liver gene expression, likely through microbial metabolites, such as butyrate and propionate that serve as epigenetic modifiers. Additionally, the production of host hormones such as primary bile acids and glucagon like peptide 1 is altered by gut microbiota to modify intermediary metabolism of the host. Summary Dysregulation of gut microbiota is implicated in various liver diseases such as alcoholic liver disease, non-alcoholic steatohepatitis, liver cirrhosis, cholangitis, and liver cancer. Gut microbiota modifiers such as probiotics and prebiotics are increasingly recognized as novel therapeutic modalities for liver and other types of human diseases.

show abstract

Fecal microbiota transplantation induces hepatitis B virus e‐antigen (HBeAg) clearance in patients with positive HBeAg after long‐term antiviral therapy

Cited by 124 publications

References 5 publications

Fecal microbiota transplantation in cancer management: Current status and perspectives

Fecal microbiota transplantation in cancer management: Current status and perspectives

Novel role of hesperidin improve obesity in HFD mice by modulating the composition of the gut microbiota

Remote Sensing Between Liver and Intestine: Importance of Microbial Metabolites

Contact Info

Product

Resources

About